TELA Bio, Inc.
TELA Bio, Inc. is listed today as TELA Bio, Inc.: market value, financials and filings are on its company page.
Funding rounds
7 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2019 | $11 M | No. 7 | $10 to $50 million | equity | SEC | |
| Nov 2018 | $2 M | No. 6 | $2 to $10 million | equity | SEC | |
| Oct 2017 | $15 M | No. 5 | $10 to $50 million | equity | SEC | |
| Jan 2017 | $7 M | No. 4 | $2 to $10 million | equity | SEC | |
| Oct 2014 | $45 M | No. 3 | $10 to $50 million | equity | SEC | |
| Aug 2013 | $6 M | No. 2 | $2 to $10 million | equity | SEC | |
| Dec 2012 | $16 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company TELA Bio, Inc., its revenue in fiscal 2025 came from these business segments: Single reportable segment $80.28 million (100%).
Annual report (SEC XBRL) · Dec 2025
TELA Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2019).
SEC Form D · Jul 2019
The industry group it chose in its notices: Other Technology.
SEC Form D · Jul 2019
Products and services#
No products or services of TELA Bio, Inc. are on record.
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Antony Koblish | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2019) | SEC Form 3 |
| Ellis Skott Greenhalgh | Person | not stated | not stated | Held Series A and B preferred stock (Form 3, 2019) | SEC Form 3 |
| Maarten Persenaire | Person | not stated | not stated | Held Series A and B preferred stock (Form 3, 2019) | SEC Form 3 |
| Nora Brennan | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2019) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| OrbiMed Capital GP IV LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Pacira BioSciences, Inc. | Company | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Quaker BioVentures Capital II, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Quaker BioVentures II LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 29 investors.
Largest shareholders today
Institutions holding TELA Bio, Inc. shares, as of Sep 30, 2026.
- Essex Woodlands Management, Inc.$9 M17.07%
- Nantahala Capital Management, LLC$8 M14.49%
- Silverarc Capital Management, LLC$2 M4.73%
- Perkins Capital Management Inc$2 M4.61%
- Vanguard Capital Management LLC$2 M3.47%
- DAFNA Capital Management LLC$2 M3.19%
- Up Strategic Wealth Investment Advisors LLC$1 M1.42%
- Sio Capital Management, LLC$1 M1.41%
- WealthTrust Axiom LLC$1 M1.22%
- Geode Capital Management, LLC$0 M0.91%
- White Pine Capital LLC$0 M0.90%
- BlackRock, Inc.$0 M0.83%
- Landscape Capital Management, L.L.C.$0 M0.68%
- Vanguard Fiduciary Trust Co$0 M0.47%
- HRT Financial LP$0 M0.28%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Antony Koblish | Executive officer | Jul 2019 |
| Francis Conway | Executive officer | Jul 2019 |
| Maarten Persenaire | Executive officer | Jul 2019 |
| Nora J. Brennan | Executive officer | Jul 2019 |
| Christopher Smith | Executive officer | Nov 2017 |
| Christine Arasin | Executive officer | Oct 2014 |
| Adele Oliva | Director | Jul 2019 |
| Antony Koblish | Director | Jul 2019 |
| Ashley Friedman | Director | Jul 2019 |
| Kurt Azarbarzin | Director | Jul 2019 |
| Matt Zuga | Director | Jul 2019 |
| Ronald J. Ellis, Jr. | Director | Jul 2019 |
| Vince Burgess | Director | Jul 2019 |
| Kevin Rakin | Director | Dec 2018 |
| Kurt Ararbarzin | Director | Dec 2018 |
| Paul Touhey | Director | Nov 2017 |
| Ashley Freidman | Director | Jan 2017 |
| Vince Burgass | Director | Jan 2017 |
| Adele C. Oliva | Director | Oct 2014 |
| Ashley C. Friedman | Director | Oct 2014 |
| Kevin C. Rakin | Director | Oct 2014 |
| Paul C. Touhey | Director | Oct 2014 |
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.